vs
Side-by-side financial comparison of Coeptis Therapeutics Holdings, Inc. (COEP) and SHF Holdings, Inc. (SHFS). Click either name above to swap in a different company.
SHF Holdings, Inc. is the larger business by last-quarter revenue ($2.1M vs $862.0K, roughly 2.4× Coeptis Therapeutics Holdings, Inc.). SHF Holdings, Inc. runs the higher net margin — -28.3% vs -146.5%, a 118.2% gap on every dollar of revenue.
Coeptis Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies, including cell therapy and antibody-based treatment candidates, to address unmet medical needs for patients with hard-to-treat malignancies. It primarily operates in the U.S., advancing its product pipeline across multiple oncology segments.
COEP vs SHFS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $862.0K | $2.1M |
| Net Profit | $-1.3M | $-582.6K |
| Gross Margin | 94.8% | — |
| Operating Margin | -230.6% | -59.1% |
| Net Margin | -146.5% | -28.3% |
| Revenue YoY | — | -43.8% |
| Net Profit YoY | 55.1% | 98.9% |
| EPS (diluted) | $0.05 | $-0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $862.0K | $2.1M | ||
| Q3 25 | $237.4K | $1.8M | ||
| Q2 25 | $200.7K | $1.8M | ||
| Q1 25 | $62.9K | $1.9M | ||
| Q4 24 | $0 | $3.7M | ||
| Q3 24 | $0 | $3.5M | ||
| Q2 24 | $0 | $4.0M | ||
| Q1 24 | $0 | $4.1M |
| Q4 25 | $-1.3M | $-582.6K | ||
| Q3 25 | $-2.9M | $179.5K | ||
| Q2 25 | $-4.3M | $-930.7K | ||
| Q1 25 | $-3.4M | $-827.2K | ||
| Q4 24 | $-2.8M | $-51.7M | ||
| Q3 24 | $-1.8M | $353.8K | ||
| Q2 24 | $-3.0M | $941.5K | ||
| Q1 24 | $-3.0M | $2.0M |
| Q4 25 | 94.8% | — | ||
| Q3 25 | 81.0% | — | ||
| Q2 25 | 77.5% | — | ||
| Q1 25 | 28.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -230.6% | -59.1% | ||
| Q3 25 | -1043.2% | -66.4% | ||
| Q2 25 | -2252.9% | -52.6% | ||
| Q1 25 | -6452.6% | -103.1% | ||
| Q4 24 | — | -215.0% | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | — | 7.4% | ||
| Q1 24 | — | 8.0% |
| Q4 25 | -146.5% | -28.3% | ||
| Q3 25 | -1220.8% | 9.8% | ||
| Q2 25 | -2159.9% | -50.4% | ||
| Q1 25 | -5440.9% | -42.8% | ||
| Q4 24 | — | -1407.1% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 23.3% | ||
| Q1 24 | — | 50.6% |
| Q4 25 | $0.05 | $-0.25 | ||
| Q3 25 | $-0.58 | $0.06 | ||
| Q2 25 | $-1.17 | $-0.33 | ||
| Q1 25 | $-1.11 | $-0.30 | ||
| Q4 24 | $-5.35 | $-18.62 | ||
| Q3 24 | $-0.05 | $0.13 | ||
| Q2 24 | $-0.08 | $0.33 | ||
| Q1 24 | $-0.08 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $676.6K | $6.8M |
| Total DebtLower is stronger | $150.0K | — |
| Stockholders' EquityBook value | $13.6M | $8.2M |
| Total Assets | $16.2M | $17.2M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $676.6K | $6.8M | ||
| Q3 25 | $421.7K | $861.7K | ||
| Q2 25 | $990.6K | $247.3K | ||
| Q1 25 | — | $931.4K | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | — | $5.9M | ||
| Q2 24 | — | $6.1M | ||
| Q1 24 | — | $5.6M |
| Q4 25 | $150.0K | — | ||
| Q3 25 | $150.0K | — | ||
| Q2 25 | $150.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $150.0K | — | ||
| Q3 24 | $1.7M | $54.8M | ||
| Q2 24 | $1.7M | $55.0M | ||
| Q1 24 | $2.3M | $58.2M |
| Q4 25 | $13.6M | $8.2M | ||
| Q3 25 | $10.4M | $7.0M | ||
| Q2 25 | $6.1M | $-17.9M | ||
| Q1 25 | $6.5M | $-16.9M | ||
| Q4 24 | $3.4M | $-12.3M | ||
| Q3 24 | $4.8M | $39.4M | ||
| Q2 24 | $-442.6K | $38.5M | ||
| Q1 24 | $-1.1M | $37.0M |
| Q4 25 | $16.2M | $17.2M | ||
| Q3 25 | $14.2M | $13.7M | ||
| Q2 25 | $12.2M | $6.0M | ||
| Q1 25 | $13.5M | $6.7M | ||
| Q4 24 | $8.9M | $13.2M | ||
| Q3 24 | $9.0M | $66.9M | ||
| Q2 24 | $4.2M | $67.3M | ||
| Q1 24 | $3.9M | $67.7M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.35× | 1.39× | ||
| Q2 24 | — | 1.43× | ||
| Q1 24 | — | 1.57× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.6M | $-1.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.6M | $-1.1M | ||
| Q3 25 | $-2.2M | $-538.0K | ||
| Q2 25 | $-2.4M | $-674.6K | ||
| Q1 25 | $-2.4M | $-1.1M | ||
| Q4 24 | $-6.6M | $-2.8M | ||
| Q3 24 | $-1.9M | $502.4K | ||
| Q2 24 | $-1.4M | $1.2M | ||
| Q1 24 | $-1.9M | $1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | -3.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | — | 1.31× | ||
| Q1 24 | — | 0.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COEP
Segment breakdown not available.
SHFS
| Investments Income | $1.2M | 56% |
| Other | $906.6K | 44% |
